The text provided includes financial information from Stryker Corporation's Form 10-Q for the third quarter of 2021. It covers various aspects such as financial statements, consolidated balance sheets, comprehensive income, cash flows, notes to the financial statements, revenue recognition, derivatives, fair value measurements, acquisitions, debt and credit facilities, leases, income taxes, segment information, asset impairments, and more. Key points include net sales figures broken down by product line and geography, details on recall matters and settlements, information on acquisitions like Gauss Surgical, Wright Medical Group N.V., and OrthoSensor, information on debt and credit facilities, estimated amortization expenses, and asset impairments related to government programs in China affecting the company's operations. The text provides detailed financial insights into Stryker Corporation’s operations and financial status for the specified period.
The text provides an overview of the financial condition and results of operations of Stryker Corporation, a leading medical technology company, for the three and nine months of 2021. It discusses the impact of the COVID-19 pandemic on their operations, various segments including Orthopedics, MedSurg, and Neurotechnology and Spine, as well as recent developments such as debt repayment and programs affecting sales in China. The text also delves into non-GAAP financial measures used, their financial liquidity, critical accounting policies, legal and regulatory matters, and forward-looking statements regarding the company's future performance and potential risks.
The text discusses the company's market risk exposure, focusing on exchange rate risk and the impacts of the COVID-19 pandemic on its operations and financial results. It mentions that quantitative and qualitative disclosures regarding exchange rate risk are detailed in the Annual Report on Form 10-K for 2020, with no material changes reported. The company states its inability to quantify the specific impacts of COVID-19 on its financial results, providing qualitative disclosures about this in its Form 10-Q and Annual Report on Form 10-K for 2020.
The text discusses the evaluation of disclosure controls and procedures by the management, including the Chief Executive Officer and Chief Financial Officer, and the conclusion that the company's controls and procedures were effective as of September 30, 2021. Additionally, it mentions that there were no changes to the internal control over financial reporting during the three months of 2021 that materially affected or are likely to affect the internal control over financial reporting.
I'm ready to summarize the text for you. Please provide the text you would like me to summarize.
I'm ready to summarize the text for you. Please go ahead and provide me with the text that needs to be summarized.
The company issued 170 shares of common stock as performance incentives to employees, which were not registered under the Securities Act of 1933. In March 2015, the Board authorized the purchase of up to $2,000 of common stock, but no shares were repurchased in the nine months of 2021. The company intends to maintain the suspension of its share repurchase program through 2021.
I understand that I will need to wait for all parts of the text before providing a summary. Please go ahead and share the text with me in parts.
I am ready to help with summarizing the text. Please go ahead and provide the text you would like me to summarize.
Stryker Corporation entered into a new revolving credit agreement on October 26, 2021, replacing the previous agreement from 2016. The new agreement features an aggregate principal amount of $2.25 billion, a maturity date of October 26, 2026, and a leverage ratio financial covenant allowing for a maximum permitted leverage ratio of 3.75:1. The agreement also includes an acquisition holiday provision that temporarily increases the maximum permitted leverage ratio to 4.75:1 in certain circumstances. Fees and interest rates under the new agreement vary based on the type of loan and the Company's credit ratings, with terms similar to the previous agreement.
The text provided includes details about exhibits related to a Credit Agreement, certifications by the Principal Executive Officer and Principal Financial Officer of Stryker Corporation, and various iXBRL documents. Additionally, it includes information about the Form 10-Q for the third quarter of 2021 for Stryker Corporation, along with signatures from Kevin A. Lobo, the Chair and Chief Executive Officer, and Glenn S. Boehnlein, the Vice President and Chief Financial Officer, dated October 29, 2021.
